Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial

Tang, WT; Ren, L; Liu, TS; Ye, QH; Wei, Y; He, GD; Lin, Q; Wang, XY; Wang, ML; Liang, F; Cui, YH; Xu, JM

Xu, JM (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Fenglin Rd 180, Shanghai 200032, Peoples R China.

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (27): 3175

Abstract

PURPOSE To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索